ARTICLE | Editor's Commentary
Biotech is healing. A house clean-up this year can help get it back on track
‘Back to normal’ is the new mantra for biotech 2023: an Editor’s Commentary
January 27, 2023 10:00 PM UTC
After a bland J.P. Morgan Healthcare Conference and a month into 2023, the biotech sector seems to still await signs of rebounding. In the last two years, the XBI has been mired in a downturn — falling 25.8% in 2022 and 20.5% in 2021— the index’s first back-to-back and largest losing record in the last 16 years.
“What’s past is prologue.” Will biotech mark another historic year of the SPDR S&P Biotech ETF (XBI) in the red? Or are we going to see a meaningful recovery this year? ...